AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MESOBLAST LTD

2.390

+0.0903.91%

Volume:7.98M

Turnover:19.00M

Market Cap:3.03B

PE:-16.20

High:2.430

Open:2.310

Low:2.300

Close:2.300

Loading ...

Overview Company News Filings

Up 810% in a year, the Mesoblast share price is surging again on Monday. Here's why

Arcadium Lithium to be Delisted From ASX 200 Index

MT Newswires Live

Mesoblast Sets Ryoncil Drug Price Ahead of Product Launch

MT Newswires Live

BRIEF-Mesoblast Says HY Loss Attributable $47.9 Million

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

THOMSON REUTERS

Press Release: Mesoblast Sets Ryoncil(R) Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Mesoblast Widens Fiscal H1 Loss as Revenue Drops

MT Newswires Live

Mesoblast Posts Fiscal H1 Loss of $0.042 Per Share, Revenue of $3.2 Million

MT Newswires Live

Mesoblast Ltd - Hy Loss Attributable $47.9 Mln

THOMSON REUTERS

Mesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Mesoblast Financial Results and Corporate Update Webcast

Mesoblast Ltd expected to post a loss of 14 cents a share - Earnings Preview

DR. Gregory George Md Phd Joins Mesoblast Board

THOMSON REUTERS

Dr. Gregory George MD PhD Joins Mesoblast Board

3 ASX Stocks Estimated To Be 31.3% To 41.2% Below Intrinsic Value

Simply Wall St.

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MSB.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.39,"timestamp":1741148600495,"preClose":2.3,"halted":0,"volume":7982810,"delay":0,"changeRate":0.03913,"change":0.09,"floatShares":735338435,"shares":1268947688,"eps":-0.14753346,"lyrEps":-0.142541,"pbRate":4.11,"amount":19003455,"amplitude":0.056522,"volumeRatio":0.995778,"dividePrice":0,"prevYearClose":3.1,"fiveDayClose":2.46,"twentyDayClose":3.02},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":735338435,"roa":"-4.85%","roe":"-21.31%","lyrEps":-0.142541,"volumeRatio":0.995778,"shares":1268947688,"dividePrice":0,"high":2.43,"amplitude":0.056522,"preClose":2.3,"low":2.3,"week52Low":0.295,"pbRate":"4.11","psRate":"334.50","week52High":3.37,"institutionHeld":0,"latestPrice":2.39,"committee":0.379233,"eps":-0.1475334601915666,"divideRate":0,"volume":7982810,"delay":0,"ttmEps":-0.1475334601915666,"open":2.31,"prevYearClose":3.1,"prevWeekClose":2.52,"prevMonthClose":2.52,"prevQuarterClose":3.1,"fiveDayClose":2.46,"twentyDayClose":3.02,"sixtyDayClose":1.67},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516574632","title":"Up 810% in a year, the Mesoblast share price is surging again on Monday. Here's why","url":"https://stock-news.laohu8.com/highlight/detail?id=2516574632","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516574632?lang=en_us&edition=fundamental","pubTime":"2025-03-03 09:10","pubTimestamp":1740964200,"startTime":"0","endTime":"0","summary":"The Mesoblast Ltd  share price is racing higher today. Again. Shares in the  S&P/ASX 300 Index  clinical-stage biotechnology company closed on Friday trading for $2.52. In earlier trade, shares were up 8.3% at $2.73 each. That saw the stock up an eye-popping 810% since this time last year. Or enough to turn an $8,000 investment into $72,800. In just 12 months. After some likely profit-taking, the Mesoblast share price is currently trading at $2.65, up 5.2%.  Here's what's grabbing ASX 200 investor interest today. Mesoblast share price benefits from its own success The ASX 200 biotech stock appears to be garnering additional tailwinds today generated by its own lengthy run higher. You see, with the Mesoblast share price having roared from 30 cents a share 12 months ago to $2.65 today, the company's market cap has surged to $3.4 billion. Why is that important?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/03/up-810-in-a-year-the-mesoblast-share-price-is-surging-again-on-monday-heres-why/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["RIO.AU","IOZ.AU","XKO.AU","BK7067","BK7501","A200.AU","LTM.AU","BK7508","MSB.AU","BK7511","BK7036","MESO","BK7095","BK7507","BK4139"],"gpt_icon":0},{"id":"2516846547","title":"Arcadium Lithium to be Delisted From ASX 200 Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2516846547","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516846547?lang=en_us&edition=fundamental","pubTime":"2025-03-03 05:31","pubTimestamp":1740951065,"startTime":"0","endTime":"0","summary":"Arcadium Lithium  will be removed from the S&P/ASX 200 index as the company will be acquired by Rio Tinto , according to a Friday Australian bourse filing.S&P Dow Jones Indices will remove Arcadium Lithium from the S&P/ASX 200 before the opening of trading on March 6 and replace it with Mesoblast , the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7511","BK4109","ALTM","LTM.AU","BK7067","BK4144","BK7508","BK7095","MSB.AU","BK7507","PLS.AU","RIO.AU","BK7501","BK7036"],"gpt_icon":0},{"id":"2514175618","title":"Mesoblast Sets Ryoncil Drug Price Ahead of Product Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2514175618","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514175618?lang=en_us&edition=fundamental","pubTime":"2025-02-27 11:09","pubTimestamp":1740625788,"startTime":"0","endTime":"0","summary":"Mesoblast  set the price for its Ryoncil mesenchymal stromal cell therapy as it seeks to launch the product in the coming weeks, according to a Thursday Australian bourse filing.Ryoncil is a mesenchymal stromal cell therapy approved by the US Food and Drug Administration on Dec. 18, 2024, as the only therapy for pediatric patients aged two months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease.The firm said its commercial execution is underway, and it is engaging with the top 45 centers representing 80% of pediatric transplants in the US.Mesoblast plans to further evaluate the immunomodulatory effects of Ryoncil on gastrointestinal inflammation in treating medically refractory pediatric Crohn's disease patients.The company's shares rose past 2% in recent trading on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","MESO","BK4139","MSB.AU","BK7067","BK7501"],"gpt_icon":1},{"id":"2514057813","title":"BRIEF-Mesoblast Says HY Loss Attributable $47.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514057813","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514057813?lang=en_us&edition=fundamental","pubTime":"2025-02-27 09:17","pubTimestamp":1740619049,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Says HY Loss Attributable $47.9 MillionFeb 27 (Reuters) - Mesoblast Ltd MSB.AX:HY LOSS ATTRIBUTABLE $47.9 MILLIONHY REVENUE $3.2 MILLIONFurther company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1XU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK4139","BK7508","BK7501","MSB.AU","MESO"],"gpt_icon":0},{"id":"2514489671","title":"Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2514489671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514489671?lang=en_us&edition=fundamental","pubTime":"2025-02-27 06:30","pubTimestamp":1740609004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nTUA8J4MXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","BK7501","MSB.AU"],"gpt_icon":0},{"id":"2514896706","title":"Press Release: Mesoblast Sets Ryoncil(R) Price Based on Economic Value of Treatment With Planned Product Availability This Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2514896706","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514896706?lang=en_us&edition=fundamental","pubTime":"2025-02-27 06:30","pubTimestamp":1740609000,"startTime":"0","endTime":"0","summary":"Mesoblast Sets Ryoncil Price Based on Economic Value of Treatment With Planned Product Availability This Quarter. Financial Results and Operational Update for Half-Year Ended December 31, 2024. NEW YORK, Feb. 26, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2024,\"Our FDA approved product Ryoncil will be available in the coming weeks to the children with SR-aGvHD in need of life-saving therapy,\" said Dr. Silviu Itescu, Chief Executive of Mesoblast. \"The treatment has delivered long-term survival outcomes in these very high-risk patients and we are pleased with the benefits and value that this treatment brings to patients and their healthcare providers at specialized transplant centers across the U.S.\". Ryoncil  U.S. Launch for Steroid-Refractory Acute Graft Versus Host Disease. FDA approved Ryoncil as the first and only therapy for pediat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","MESO","BK4139","MMAT","MSB.AU","MSC","BK4588","03160","BK4150","BK4141","ODD","R","BK4585","BK7508","CD","ORR","WAC","BK7067","BK4099","BK7501","BK4116","BK4170","BK4546","BK4161","BK4183","BK4232","BK4555","IBD","DDD","BK4551","BK4575","BK4604","TM"],"gpt_icon":1},{"id":"2514893718","title":"Mesoblast Widens Fiscal H1 Loss as Revenue Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2514893718","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514893718?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:51","pubTimestamp":1740606707,"startTime":"0","endTime":"0","summary":"Mesoblast  reported Thursday a fiscal first-half loss of $0.042 per diluted share, compared with a loss of $0.0372 a year earlier.Analysts surveyed by Visible Alpha expected a loss of $0.05.Revenue for the six months ended Dec. 31, 2024, was $3.2 million, down from $3.4 million a year earlier. Analysts surveyed by Visible Alpha expected $3 million.The board did not declare a dividend and \"do not anticipate paying dividends in the foreseeable future,\" per the filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MESO","MSB.AU"],"gpt_icon":0},{"id":"2514389358","title":"Mesoblast Posts Fiscal H1 Loss of $0.042 Per Share, Revenue of $3.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514389358","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514389358?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:41","pubTimestamp":1740606081,"startTime":"0","endTime":"0","summary":"Mesoblast Posts Fiscal H1 Loss of $0.042 Per Share, Revenue of $3.2 Million","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MESO","MSB.AU"],"gpt_icon":0},{"id":"2514689388","title":"Mesoblast Ltd - Hy Loss Attributable $47.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514689388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514689388?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:39","pubTimestamp":1740605952,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1XU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7508","MESO","MSB.AU","BK4139"],"gpt_icon":0},{"id":"2514868686","title":"Mesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2514868686","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514868686?lang=en_us&edition=fundamental","pubTime":"2025-02-26 22:55","pubTimestamp":1740581713,"startTime":"0","endTime":"0","summary":"A downtrend has been apparent in Mesoblast Limited  lately. While the stock has lost 10.8% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the stock. On the fundamental side, strong agreement among Wall Street analysts in raising earnings estimates for this company enhances its prospects of a trend reversal.Understanding Hammer Chart and the Technique to Trade It. If this is not enough, you should note that MESO currently has a Zacks Rank #2 , which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS su","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-limited-meso-could-support-145513668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MSB.AU","BK4139","MESO"],"gpt_icon":0},{"id":"2514023959","title":"Mesoblast Financial Results and Corporate Update Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2514023959","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514023959?lang=en_us&edition=fundamental","pubTime":"2025-02-26 07:13","pubTimestamp":1740525180,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 25, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2024.The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com. About Mesoblast Mesoblast  is a world leader in developing allogeneic  cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.Mesoblast’s RYONCIL  for the treatment of steroid-refractory acute graft versus host disease  in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-financial-results-corporate-webcast-231300053.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","MSB.AU","MSC","BK4150","MESO","MSB","BK4139","BK4575"],"gpt_icon":0},{"id":"2514062464","title":"Mesoblast Ltd  expected to post a loss of 14 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2514062464","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514062464?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:12","pubTimestamp":1740481943,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd  expected to post a loss of14cents a share - Earnings Preview Mesoblast Ltd MESO.OQ, MESO.O is expected to report resultson February 27 for the period ending September 30 2024The Melbour","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL5N3PG0VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","MSB.AU"],"gpt_icon":0},{"id":"2513667287","title":"DR. Gregory George Md Phd Joins Mesoblast Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2513667287","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513667287?lang=en_us&edition=fundamental","pubTime":"2025-02-24 07:33","pubTimestamp":1740353633,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250223:nTUA39FYLJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7067","BK7501","BK7508"],"gpt_icon":0},{"id":"2513769339","title":"Dr. Gregory George MD PhD Joins Mesoblast Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2513769339","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513769339?lang=en_us&edition=fundamental","pubTime":"2025-02-24 07:33","pubTimestamp":1740353580,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 23, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast’s largest shareholder, to its Board of Directors.Dr. George founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development. Dr. George brings to the Board his background as a medical scientist with unique operational experience having built a start-up company in the medical field and turning it into a highly-efficient multi-billion-dollar commercial organization.Mesoblast Founder and Chief Executive Dr. Silviu Itescu said, “Greg’s unique operational skills and insights will provide tremendous value as Mesoblast transitions to become an efficient commercial organization.”Mesoblast is committed to developing additional cell therapies for distinct","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dr-gregory-george-md-phd-233300998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4006","BK7067","MSC","MMAT","BK4196","BK4141","MD","BK4575","BK4139","MSB","BK7508","BK4150","BK7501","MSB.AU","MESO"],"gpt_icon":0},{"id":"2512364851","title":"3 ASX Stocks Estimated To Be 31.3% To 41.2% Below Intrinsic Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2512364851","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512364851?lang=en_us&edition=fundamental","pubTime":"2025-02-18 16:02","pubTimestamp":1739865741,"startTime":"0","endTime":"0","summary":"The Australian market is currently navigating a complex landscape, with the Reserve Bank of Australia's recent interest rate cut and mixed sector performances highlighting the challenges and opportunities for investors. In this environment, identifying undervalued stocks can be particularly rewarding, as they may offer potential growth when their intrinsic value is recognized by the market.Top 10 Undervalued Stocks Based On Cash Flows In Australia. Audinate Group is trading at A$10.41, significantly undervalued compared to its estimated fair value of A$16.03, suggesting potential upside based on discounted cash flow analysis. Despite a challenging financial period with a net loss of A$2.21 million and reduced profit margins, earnings are forecast to grow substantially at 51% annually, outpacing the Australian market's growth rate. However, return on equity remains low at 6.8%, indicating room for improvement in profitability metrics.PolyNovo is trading at A$1.92, below its fair value e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-asx-stocks-estimated-31-080221754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7094","BK7090","MLG.AU","BK7506","BK7064","MAD.AU","SYL.AU","BK7126","AD8.AU","XKO.AU","BK7083","BK7055","IEL.AU","BK7124","BK7073","BK7508","XAO.AU","XJO.AU","SFR.AU","BK7110","RDY.AU","BK7507","BK7067","WHC.AU","MSB.AU","IDX.AU","BK7132","ALX.AU","BK7095","ALC.AU","BK7503","PNV.AU","BK7016","BK7501"],"gpt_icon":0},{"id":"2511019645","title":"Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2511019645","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511019645?lang=en_us&edition=fundamental","pubTime":"2025-02-14 07:37","pubTimestamp":1739489856,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nTUA8M8KDT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MSB.AU","BK7501","BK7067"],"gpt_icon":0}],"pageSize":16,"totalPage":10,"pageCount":1,"totalSize":152}]}}